However, it is promising that having active anticancer response, rich immune network with CD8 cells and high PD-1-PD-L1 axis and, probably, tumour mutational burden (TMB) patients with COPD could have benefit from immunotherapy with ICIs. The gene discussed is CD8A; the disease is neoplasm.